Location, location, timing: Analysis of cytomegalovirus epitopes for neutralizing antibodies

Immunology Letters

Volumn 112, Issue 1, 2007, Pages 58-60

  Schrader, John W ^a   McLean, Gary R ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Epitope; gB; Human cytomegalovirus; Neutralizing antibodies; Vaccine

Indexed keywords

ANTIGENIC DOMAIN 1; ANTIGENIC DOMAIN 2; CYTOMEGALOVIRUS VACCINE; EPITOPE; GLYCOPROTEIN B; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

AMINO TERMINAL SEQUENCE; ANTIBODY RESPONSE; B LYMPHOCYTE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; COMPLEMENTARITY DETERMINING REGION; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMORAL IMMUNITY; LETTER; OPSONIZATION; PRIORITY JOURNAL;

ANTIBODIES, VIRAL; ANTIBODY FORMATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; EPITOPE MAPPING; HUMANS; IMMUNODOMINANT EPITOPES; NEUTRALIZATION TESTS; PROTEIN CONFORMATION; TIME FACTORS; VIRAL ENVELOPE PROTEINS;

EID: 34548220988     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2007.07.001     Document Type: Letter

References (13)

1. Khanna R., and Diamond D.J. Human cytomegalovirus vaccine: time to look for alternative options. Trends Mol Med 12 (2006) 26-33
2. Nigro G., Adler S.P., La Torre R., and Best A.M. Congenital cytomegalovirus collaborating group passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353 (2005) 1350-1362
3. Britt W.J., Vulger L., Butfiloski E.J., and Stephens E.B. Cell surface expression of human cytomegalovirus (HCMV) gp55-116(gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 64 (1990) 1079-1085
4. Ohizumi Y., Suzuki H., Matsumoto Y., Masuho Y., and Numazaki Y. Neutralizing mechanisms of two human monoclonal antibodies against human cytomegalovirus glycoprotein 130/55. J Gen Virol 73 (1992) 2705-2707
5. Ohlin M., Sundqvist V.A., Mach M., Wahren B., and Borrebaeck C.A. Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. J Virol 67 (1993) 703-710
6. McLean G.R., Olsen O.A., Watt I.N., Rathanaswami P., Leslie K.B., Babcook J.S., et al. Recognition of human cytomegalovirus by human primary immunoglobulins identifies an innate foundation to an adaptive immune response. J Immunol 174 (2005) 4768-4778
7. Schoppel K., Kropff B., Schmidt C., Vornhagen R., and Mach M. The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies. J Infect Dis 175 (1997) 533-544
8. Ayata M., Sugano T., Murayama T., Sakamuro D., Takegami T., Matsumoto Y., et al. Different antibody response to a neutralizing epitope of human cytomegalovirus glycoprotein B among seropositive individuals. J Med Virol 43 (1994) 386-392
9. Marshall G.S., Li M., Stout G.G., Louthan M.V., Duliege A.M., Burke R.L., et al. Antibodies to the major linear neutralizing domains of cytomegalovirus glycoprotein B among natural seropositives and CMV subunit vaccine recipients. Viral Immunol 13 (2000) 329-341
10. Loenen W.A., Bruggeman C.A., and Wiertz E.J. Immune evasion by human cytomegalovirus: lessons in immunology and cell biology. Semin Immunol 13 (2001) 41-49
11. Heldwein E.E., Lou H., Bender F.C., Cohen G.H., Eisenberg R.J., and Harrison S.C. Crystal structure of glycoprotein B from herpes simplex virus 1. Science 313 (2006) 217-220
12. Britt W.J., Jarvis M.A., Drummond D.D., and Mach M. Antigenic domain 1 is required for oligomerization of human cytomegalovirus glycoprotein B. J Virol 79 (2005) 4066-4079
13. Yue Y., Kaur A., Eberhardt M.K., Kassis N., Zhou S.S., Tarantal A.F., et al. Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques. J Virol 81 (2007) 1095-1109